The article offers updates related to breast cancer treatment in the U.S. ImClone Systems Inc. has initiated patient enrollment for its disease-directed randomized Phase II clinical trial of IMC-A12 in breast cancer patients. Genentech Inc. has announced that a Phase III study of Avastin met its primary endpoint of increasing the time patients life. Abraxis BioScience Inc. has entered into an agreement with AstraZeneca to reacquire the exclusive rights to market Abraxane in the country.
Processing Request
No Comments.